{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Etrolizumab", "query": { "intervention": "Etrolizumab" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 12, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Etrolizumab&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-14T05:38:47.751Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02100696", "title": "A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Etrozulimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 609, "start_date": "2014-05-21", "completion_date": "2020-04-16", "has_results": true, "last_update_posted_date": "2021-08-13", "last_synced_at": "2026-09-14T05:38:47.751Z", "location_count": 38, "location_summary": "Birmingham, Alabama • La Jolla, California • San Diego, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02100696" }, { "nct_id": "NCT02996019", "title": "A Study to Compare Pharmacokinetics (PK) of Etrolizumab Administered Subcutaneously by a Prefilled Syringe With Needle Safety Device (PFS-NSD) or an Auto-injector (AI)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Etrolizumab", "type": "DRUG" }, { "name": "Auto-Injector (AI)", "type": "DEVICE" }, { "name": "Prefilled Syringe With Needle Safety Device (PFS-NSD)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 180, "start_date": "2016-12-07", "completion_date": "2018-04-09", "has_results": false, "last_update_posted_date": "2018-12-03", "last_synced_at": "2026-09-14T05:38:47.751Z", "location_count": 4, "location_summary": "Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas + 1 more", "locations": [ { "city": "Daytona Beach", "state": "Florida" }, { "city": "Evansville", "state": "Indiana" }, { "city": "Dallas", "state": "Texas" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02996019" }, { "nct_id": "NCT02171429", "title": "A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Adalimumab", "type": "DRUG" }, { "name": "Adalimumab Placebo", "type": "OTHER" }, { "name": "Etrolizumab", "type": "DRUG" }, { "name": "Etrolizumab Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 358, "start_date": "2014-11-14", "completion_date": "2020-05-25", "has_results": true, "last_update_posted_date": "2021-07-23", "last_synced_at": "2026-09-14T05:38:47.751Z", "location_count": 4, "location_summary": "Orlando, Florida • Topeka, Kansas • Mentor, Ohio", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Topeka", "state": "Kansas" }, { "city": "Mentor", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02171429" }, { "nct_id": "NCT01461317", "title": "Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Etrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 121, "start_date": "2011-11-29", "completion_date": "2016-08-07", "has_results": false, "last_update_posted_date": "2020-02-10", "last_synced_at": "2026-09-14T05:38:47.751Z", "location_count": 5, "location_summary": "La Jolla, California • Atlanta, Georgia • Rochester, Minnesota + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Great Neck", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01461317" }, { "nct_id": "NCT02629744", "title": "A Study to Evaluate Pain, Tolerability, Safety, and Usability of a Single Self-administered Etrolizumab by Auto-injector in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "Etrolizumab", "type": "DRUG" }, { "name": "Prefilled Auto-injector (Rotaject)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 27, "start_date": "2015-12", "completion_date": "2016-06", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-09-14T05:38:47.751Z", "location_count": 2, "location_summary": "Cypress, California • Dallas, Texas", "locations": [ { "city": "Cypress", "state": "California" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02629744" }, { "nct_id": "NCT02165215", "title": "A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colitis, Ulcerative" ], "interventions": [ { "name": "Etrolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 359, "start_date": "2014-08-12", "completion_date": "2020-04-06", "has_results": true, "last_update_posted_date": "2021-08-19", "last_synced_at": "2026-09-14T05:38:47.751Z", "location_count": 33, "location_summary": "Orange, California • San Diego, California • San Francisco, California + 29 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Ventura", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02165215" }, { "nct_id": "NCT02394028", "title": "A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn Disease" ], "interventions": [ { "name": "Etrolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 1035, "start_date": "2015-03-20", "completion_date": "2021-09-07", "has_results": true, "last_update_posted_date": "2022-11-16", "last_synced_at": "2026-09-14T05:38:47.751Z", "location_count": 62, "location_summary": "Arcadia, California • La Jolla, California • Long Beach, California + 53 more", "locations": [ { "city": "Arcadia", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "San Carlos", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02394028" }, { "nct_id": "NCT00694980", "title": "A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "placebo", "type": "DRUG" }, { "name": "rhuMAb Beta7", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 48, "start_date": "2008-09", "completion_date": "2012-09", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-09-14T05:38:47.751Z", "location_count": 8, "location_summary": "Anniston, Alabama • San Francisco, California • Gainesville, Florida + 5 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT00694980" }, { "nct_id": "NCT02118584", "title": "Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Etrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1822, "start_date": "2014-09-15", "completion_date": "2023-10-05", "has_results": true, "last_update_posted_date": "2024-10-23", "last_synced_at": "2026-09-14T05:38:47.751Z", "location_count": 57, "location_summary": "Birmingham, Alabama • La Jolla, California • Orange, California + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02118584" }, { "nct_id": "NCT02403323", "title": "Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn Disease" ], "interventions": [ { "name": "Etrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 790, "start_date": "2015-06-08", "completion_date": "2023-10-09", "has_results": true, "last_update_posted_date": "2024-12-02", "last_synced_at": "2026-09-14T05:38:47.751Z", "location_count": 59, "location_summary": "Arcadia, California • La Jolla, California • Long Beach, California + 51 more", "locations": [ { "city": "Arcadia", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "San Carlos", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02403323" } ] }